Abstract
The direct causes of neurodegeneration underlying Alzheimer’s disease (AD) and many other dementias, are not known. Here we identify serum amyloid P component (SAP), a constitutive plasma protein normally excluded from the brain, as a potential drug target. After meta-analysis of three genome-wide association studies, comprising 44,288 participants, cis-Mendelian randomization showed that genes responsible for higher plasma SAP values are significantly associated with AD, Lewy body dementia and plasma tau concentration. These genetic findings are consistent with experimental evidence of SAP neurotoxicity and the strong, independent association of neocortex SAP content with dementia at death. Depletion of SAP from the blood and from the brain, as is provided by the safe, well tolerated, experimental drug, miridesap, may therefore contribute to treatment of neurodegeneration.
Competing Interest Statement
AFS and CF have received funding from NewAmsterdam Pharma for unrelated work. MBP is the inventor on expired patents on SAP depletion by miridesap (CPHPC). GlaxoSmithKline's abandoned patents on an experimental miridesap prodrug are assigned to UCL spinout company, Pentraxin Therapeutics Ltd, founded and directed by MBP. The other authors have no competing interests.
Funding Statement
AFS is supported by BHF grant PG/18/5033837, PG/22/10989, and the UCL BHF Research Accelerator AA/18/6/34223. This work was supported by the National Institutes of Health (USA) [R01 LM010098], as well as by the UKRI/NIHR Multimorbidity Fund Mechanism and Therapeutics Research Collaborative MR/V033867/1. Core support for the work of MBP was provided by the UK National Institute for Health Research (NIHR) Biomedical Research Centre and Unit Funding Scheme via the University College London Hospitals/University College London Biomedical Research Centre. MNR is supported by the National Institute for Health Research, (NIHR) University College London Hospitals (UCLH)/ University College London (UCL) Biomedical Research Centre (BRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics declaration: The study exclusively uses information from aggregate data resources. As such this study is exempt from approval by an Ethics Committee or Institutional Review Board. Data and materials availability: All of the source data for this study are publicly available: SAP plasma value from DECODE (https://download.decode.is/form/folder/proteomics), AGES (https://doi.org/10.5281/zenodo.5711426), and Interval (https://www.ebi.ac.uk/gwas/studies/GCST90242796). Data on CRP concentration were obtained from: https://www.ebi.ac.uk/gwas/studies/GCST90029070. GWAS data were accessed for the following traits: Alzheimer's disease (https://www.niagads.org/datasets/ng00075), Lewy body dementia (https://www.ebi.ac.uk/gwas/publications/33589841), osteoarthritis (https://www.ebi.ac.uk/gwas/publications/30664745), systemic lupus erythematosus (https://www.ebi.ac.uk/gwas/publications/26502338), idiopathic pulmonary fibrosis, (https://www.ebi.ac.uk/gwas/publications/33197388), systolic/diastolic blood pressure (https://www.ebi.ac.uk/gwas/publications/30224653), coronary heart disease (https://www.ebi.ac.uk/gwas/publications/36474045), type 2 diabetes (http://diagram-consortium.org/downloads.html, from Mahajan et al.), liver enzymes (https://www.ebi.ac.uk/gwas/publications/33972514 and https://www.ebi.ac.uk/gwas/publications/33547301), brain volume (https://ctg.cncr.nl/software/summary_statistics, from Jansen et al.), cerebral white matter hyperintensities (https://www.ebi.ac.uk/gwas/publications/26674333), circulating total tau values (https://www.ebi.ac.uk/gwas/publications/35396452). All data needed to evaluate the conclusions in the paper are present in the paper and the Supplementary Materials.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
One Sentence Summary: Genetic analyses of circulating serum amyloid P component (SAP) values suggest that depletion of plasma SAP may decrease the risk of Alzheimer’s disease and Lewy body dementia.